LITERATURE REVIEW ON MORBIDITY AND MORTALITY ENDPOINTS IN MELANOMA PATIENTS UNDER TREATMENT WITH GM-CSF OR DACARBAZINE

Author(s)

Lebioda A1, Draheim C2, Kulp W2
1Amgen GmbH, Munich, Germany, 2Xcenda GmbH, Hannover, Germany

OBJECTIVES:  Two systematic literature reviews were conducted to assess morbidity and mortality endpoints in patients with stage III or IV melanoma in response to treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) or dacarbazine (DTIC). METHODS:  For this purpose, two literature searches were conducted in the bibliographic databases such as MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials. The systematic literature reviews were based on PICO-(

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN25

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Oncology

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×